Sign in
Not yet recruitingPhase 3

Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.

Key facts

Who runs it
Nanjing Zenshine Pharmaceuticals
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
858 people, planned
Started
7 Nov 2026
Expected to end
30 Jan 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Sebaloxavir marboxil
  • Placebo
Record updated
28 July 2026

Who can take part

Age
2 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • 1. The index participant (aged ≥18 years), or the index participant (aged <18 years) together with their legal guardian, understands and voluntarily provides written informed consent form (ICF). The index participant must be ≥1 year of age at the time of ICF signing, with no gender restriction
  • 2. The index participant must be the first case of influenza virus infection in the household during the current influenza season
  • 3. The index participant must have a positive result from a rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) assay
  • 4. At the time of HHC randomization, the interval from the onset of the index participant's initial influenza symptoms to informed consent must be ≤48 hours. Symptom onset is defined as: first axillary temperature ≥37.5°C, or the presence of at least one other influenza symptom
  • 5. The index participant must not have used any anti-influenza antiviral medications (including traditional Chinese medicines or Western medicines) since symptom onset, and must be willing to receive oseltamivir phosphate treatment after signing informed consent form
  • 1. Aged ≥2 years at the time of randomization, with no gender restriction
  • 2. Has been living in the same household with the index participant for at least 48 hours at the time of randomization
  • 3. Is able to reside with the index participant from screening/randomization through Day 10 (must live in the same household with the index participant for at least 7 days)
  • 4. Tests negative by rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR)
  • 5. Meets all of the following criteria and is judged by the investigator to have no influenza virus infection:; Axillary temperature <37°C at screening; No influenza-related symptoms at screening (such as nasal congestion, sore throat, cough, myalgia or arthralgia, fatigue, headache, chills/sweating, or other influenza symptoms assessed by the investigator)
  • 6. The HHC is ≥18 years of age, or the HHC is <18 years of age and together with their parent(s)/legal guardian(s) understands and voluntarily signs the informed consent form (ICF), and agrees to comply with all study procedures, including completion of diary cards (the guardian may assist in assessment/completion)
  • 7. The HHC must sign the informed consent form (ICF) within 24 hours after the index participant signs the ICF
  • 8. The HHC and their partner must agree to practice complete abstinence or use effective contraceptive measures from screening through 3 months after the end of study drug administration

Who cannot take part

  • 1. Participants with suspected hypersensitivity to the active pharmaceutical ingredients or excipients of the investigational product
  • 2. Participants whose household contacts or other family members (excluding the index participant) have been diagnosed with influenza within 3 months before randomization
  • 4. Participants requiring systemic (oral or injectable) or intranasal antipyretic/analgesic agents, corticosteroids, or immunosuppressants (those using topical preparations are allowed)
  • 5. Participants who have received an influenza vaccine within 6 months prior to screening
  • 6. Participants who have taken anti-influenza Chinese or Western medications within 30 days prior to screening, including but not limited to neuraminidase inhibitors, hemagglutinin inhibitors, M2 ion channel blockers, cap-dependent endonuclease (CEN) inhibitors, and heat-clearing/detoxifying Chinese herbal medicines, such as oseltamivir, zanamivir, peramivir, laninamivir, umifenovir, favipiravir, rimantadine, amantadine, arbidol, nitazoxanide, baloxavir, Lianhua Qingwen capsules/granules, Jinhua Qinggan granules*, etc
  • 11. Immunocompromised participants, including those with malignancies, history of organ or bone marrow transplantation, HIV infection, or use of immunosuppressants within the previous 3 months
  • 14. Participants who have participated in another interventional clinical trial of a drug or medical device within 30 days before screening
  • 1. Participants who are diagnosed with bacterial or other non-influenza virus infections at screening requiring systemic antibacterial or antiviral treatment
  • 2. Participants with suspected hypersensitivity to the active ingredients or excipients of oseltamivir phosphate oral suspension/capsules; Household contact:
  • 7. Participants with active infection or requiring systemic anti-infective treatment at screening (topical therapy for mild skin infections is allowed)
  • 8. Participants with other respiratory viral infections
  • 9. Participants with difficulty swallowing study medication or a history of gastrointestinal disorders that may significantly impair drug absorption, including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, or post-gastrectomy
  • 13. Participants with suspected or confirmed alcohol abuse (defined as weekly consumption of >14 units of alcohol; 1 unit = 360 mL beer, 45 mL of 40% spirits, or 150 mL of 12% wine) or history of drug abuse
  • 16. Participants with any other conditions that, in the judgment of the investigator, would preclude enrollment in the study
  • 3. Participants who have been cohabiting with other family members exhibiting influenza-like symptoms (axillary temperature ≥37.5°C, nasal congestion, sore throat, cough, myalgia/arthralgia, fatigue, headache, chills/sweating, or other influenza symptoms as assessed by the investigator) other than on the screening day
  • 10. Participants with severe underlying comorbidities, defined as Grade 3 or higher per the Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0
  • 12. HHCs requiring long-term use of aspirin- or salicylate-containing products, defined as daily regular use for more than 14 consecutive days
  • 15. Women who have a positive pregnancy test result or are currently lactating

Other criteria

  • Index Participants:

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a randomized, double-blind, placebo-controlled phase III clinical trial. The trial participants include index participants (IP) and household contacts (HHC). A total of 536 index participants (the first person in the household diagnosed with influenza) and 858 household contacts (family members living with the index participant) are planned to be enrolled. After the index participants and their household contacts have signed informed consent form and passed screening eligibility, randomization will be performed at the household level in a 1:1 ratio, stratifying by the time from onset of the index participant's initial influenza symptoms to signing of informed consent form (<24 hours, ≥24 hours), index participant's viral subtype (influenza A, influenza B), and household contact's age (<12 years, ≥12 years). Household contacts will be assigned to either the Sebaloxavir marboxil group or the placebo group. The study objective is to compare the prophylactic efficacy and safety of Sebaloxavir marboxil tablets/oral suspension versus placebo in household contacts (HHCs).

The 2 groups in the trial

  • Sebaloxavir marboxil groupTreatment being tested

    Treatment: Sebaloxavir marboxil

  • Placebo groupPlacebo, for comparison

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.
Record updated
28 July 2026